How should Lupolar (generic) and bevacizumab be dosed according to the patient's creatinine clearance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bevacizumab Dose Adjustment Based on Creatinine Clearance

No dose adjustment of bevacizumab is required based on creatinine clearance. The FDA-approved prescribing information explicitly states that no dose adjustment is recommended based on renal function 1.

Bevacizumab Dosing in Renal Impairment

Bevacizumab pharmacokinetics are not significantly affected by renal function because it is a large monoclonal antibody (149 kDa) that is eliminated primarily through protein catabolism rather than renal excretion 1. The population pharmacokinetic analysis of 491 patients demonstrated that:

  • Clearance varies by body weight, sex, and tumor burden—but NOT by renal function 1
  • Mean clearance is 0.23 L/day with an estimated half-life of 20 days 1
  • After correcting for body weight, males have higher clearance (0.26 L/day) compared to females (0.21 L/day) 1

Standard Dosing Regimens

Use the following doses without modification for renal impairment 2, 1:

  • 5 mg/kg IV every 2 weeks (most common in colorectal cancer)
  • 7.5 mg/kg IV every 3 weeks (alternative regimen)
  • 10 mg/kg IV every 2 weeks (in some protocols)
  • 15 mg/kg IV every 3 weeks (in certain indications)

Bevacizumab may be safely administered at a rate of 0.5 mg/kg/min (e.g., 5 mg/kg over 10 minutes, 7.5 mg/kg over 15 minutes) 2.

Important Caveat: Proteinuria Monitoring

While dose adjustment for baseline renal impairment is not required, bevacizumab itself causes proteinuria as an adverse event. Recent evidence shows that proteinuria can increase bevacizumab clearance 3:

  • Patients with higher urinary protein-to-creatinine ratio (UPCR) had lower serum bevacizumab concentrations
  • Grade 3 proteinuria decreased median trough concentrations by 31.5% compared to grade 0 3
  • Monitor for proteinuria development during treatment, as this may affect drug exposure

Regarding "Lupolar"

"Lupolar" is not a recognized generic or brand name medication in standard pharmaceutical references. If this refers to a specific chemotherapy agent used in combination with bevacizumab, please clarify the drug name. Common combinations include:

  • Pemetrexed (requires dose adjustment for CrCl <45 mL/min—contraindicated in severe renal impairment)
  • Carboplatin (requires dose adjustment based on renal function using Calvert formula)
  • Fluorouracil/leucovorin (generally no adjustment needed)

If you meant a different agent, the dosing recommendations would differ significantly.

References

Guideline

colon cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.